# Melinda Gooderham

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/melinda-gooderham/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,115 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 60 |
| i10-index | 199 |
| Last Known Institution | Queen's University |
| OpenAlex ID | https://openalex.org/A5006526834 |
| ORCID iD | 0000-0001-8926-0113 |
| Works | 579 |

## Researcher papers

Showing 12 of 13.

- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)](https://scholariq.org/papers/efficacy-and-safety-of-apremilast-an-oral-phosphodiesterase-4-inhibitor-in/)
- [Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis](https://scholariq.org/papers/phase-2-trial-of-selective-tyrosine-kinase-2-inhibition-in-psoriasis/)
- [Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial](https://scholariq.org/papers/topical-tofacitinib-for-atopic-dermatitis-a-phase-scp-ii-scp-a-randomized-trial/)
- [Bimekizumab versus Secukinumab in Plaque Psoriasis](https://scholariq.org/papers/bimekizumab-versus-secukinumab-in-plaque-psoriasis/)
- [Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-abrocitinib-in-patients-with-moderate-to-severe-atopic/)
- [Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-with-concomitant-topical-corticosteroids-in/)
- [Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial](https://scholariq.org/papers/deucravacitinib-versus-placebo-and-apremilast-in-moderate-to-severe-plaque/)
- [The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)](https://scholariq.org/papers/the-efficacy-and-safety-of-apremilast-etanercept-and-placebo-in-patients-with/)
- [Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-lebrikizumab-in-combination-with-topical-corticosteroids/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Queen's University](https://scholariq.org/institutions/queen-s-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.